Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer

By Osako Tomo   Ito Yoshinori   Takahashi Shunji   Tokudome Nahomi   Iwase Takuji   Hatake Kiyohiko  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 159-164

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

By Gasparini Giampietro   Gion Massimo   Mariani Luigi   Papaldo Paola   Crivellari Diana   Filippelli Gianfranco   Morabito Alessandro   Silingardi Vittorio   Torino Francesco   Spada Antonella   Zancan Matelda   Sio Livia   Caputo Antonio   Cognetti Francesco   Lambiase Antonio   Amadori Dino  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 355-365

Springer Publishing Company

Access to resources Recommend Favorite

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

By Somlo G.   Martel C.   Lau S.   Frankel P.   Ruel C.   Gu L.   Hurria A.   Chung C.   Luu T.   Morgan R.   Leong L.   Koczywas M.   McNamara M.   Russell C.   Kane S.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 899-906

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

By Eiermann W.  

Annals of Oncology, Vol. 12, Iss. 12, 2001-12 ,pp. : 57-62

Springer Publishing Company

Access to resources Recommend Favorite